ABSTRACT: Background. Research has reported relationships between 3-dimensional (3D) radiation dose to head and neck structures and consequential swallowing/nutritional outcomes. However, this evidence is preliminary. The current study aimed to identify which reported dose constraints identified functional impairment at 6 months posttreatment. Methods. Dose constraints with reported relationships to swallowing and nutrition were identified through a systematic literature review. Dose-volume histograms for 12 patients with T1-T3 oropharyngeal cancer treated with 3D conformal radiotherapy determined dosages delivered to specific structures. Doses were examined in relation to published dose constraints and the swallowing and nutritional outcomes at 6 months posttreatment.
INTRODUCTION
The move from 2-dimensional (2D) radiotherapy planning to 3-dimensional (3D) planning has allowed more detailed reporting of radiation dose in relation to tissue volumes, that is, the amount of radiation provided as a percentage volume to a structure of interest, such as the base of tongue (BOT). In the past, maximum point doses were stipulated by normal tissue tolerances and these were typically applied only to critical normal tissues, such as the spinal cord. In the past 10 years, however, there has been a concerted effort to achieve greater understanding of the possible relationship between submaximal point dosages provided to various other structures, such as those specifically involved in swallowing, in an attempt to better understand the consequential impact of radiation dose on swallowing, and subsequently nutrition.
Treatment intensification (with altered fractionation radiotherapy, chemotherapy, or targeted therapy [eg, cetuximab] ) for head and neck cancer has been shown to improve survival compared with conventional radiotherapy treatment. [1] [2] [3] These approaches, however, have been associated with increased acute toxicity, which has resulted in negative functional sequelae for both swallowing and nutrition. 4 Improved treatment delivery with 3D conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) has allowed intensified treatment to be delivered while allowing more of the normal tissue to be spared, 5 with the potential to optimize the functional outcomes of swallowing and nutrition. Previously, swallowing dysfunction has been reported in 30% to 50% of patients treated with intensive nonsurgical regimens 6, 7 and has been negatively correlated with quality of life 12 months posttreatment. 8 Dysphagia has also been associated with anxiety and depression in survivors of head and neck cancer. 9 Determining which patients will develop swallowing dysfunction following nonsurgical treatment for head and neck cancer, however, is challenging.
Recent evidence has examined the dosimetric parameters of specific swallowing organs at risk and their impact on posttreatment dysphagia and nutrition. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Dose-volume histograms are routinely used in the 3D planning of radiotherapy for the assessment and reporting of dose to treatment volumes and organ at risk, and to ensure quality assurance, adequate dose to target structures, and avoidance of dose to nearby anatomic structures. 24 Dose-volume histograms can also be generated posttreatment to determine the specific radiotherapy mean, maximum, and partial doses received by each swallowing organ at risk within the treatment field. Each organ at risk can have a dose-volume histogram generated for it, which demonstrates the volume of that organ receiving the dose. For example, a V 35 of 80% to the inferior pharyngeal constrictor (see dashed line dose-volume histogram in Figure 1 ) would indicate that 80% (y-axis) of the inferior pharyngeal constrictor received a total of 35 Gy (x-axis).
It has been hypothesized that the mean, maximum, and partial doses delivered to a particular swallowing organ at risk may have a long-term impact on swallowing function, and that reduction of dose to these structures may help to minimize dysphagia and poor nutrition posttreatment. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] 25 Eisbruch and colleagues 4 were the first to question an association between dose-volume parameters and dysphagia. They studied 32 patients with locally advanced head and neck cancer who were treated with 2 chemoradiation protocols associated with high rates of dysphagia and found a significant increase in tissue thickness of the pharyngeal constrictors, supraglottic larynx, and glottic larynx posttreatment. This enabled these authors to label these organs at risk as ''dysphagia/aspiration related structures,'' and an initial dose limitation of 50 Gy to the pharynx was suggested to avoid stricture at this site. 4 Subsequent studies have used the anatomic swallowing organ at risk and contouring recommendations suggested by Eisbruch et al 4 to provide further evidence for minimizing dysphagia. Literature published recently has also indicated relationships between the requirement of alternative feeding and dose-volume parameters. 21 Investigations of additional critical parameters such as nutritional status or percentage weight loss and their relation to dose delivered to the swallowing organ at risk are still yet to be explored.
Enhanced understanding of the relationships between certain radiation dose levels and potential negative treatment effects will ultimately lead to informed treatment planning, optimization of patient outcomes, and greater prognostic decision making regarding patients most at risk for dysphagia and nutritional compromise following treatment. However, as yet this area of research is in the early preliminary stages. Thus, the aims of the current report are 2-fold: (1) to critically review the current literature and compile the published mean, maximum, and partial dosimetric parameters to organs at risk that have been implicated in swallowing outcomes to date; and (2) to examine the radiation dose information of a cohort who received 3D conformal altered fractionation radiotherapy with concomitant boost (AFRT-CB) for oropharyngeal cancer, with a range of functional outcomes assessed at 6 months posttreatment. The purpose of this will be to highlight how well the dose constraints reported in the literature to date relate to a range of . The x-axis refers to the Gray (Gy) dose delivered, and the y-axis refers to the percentage (%) of the organ receiving the dose (Gy).
detailed swallowing and nutritional outcomes at 6 months posttreatment.
MATERIALS AND METHODS

Review of the current literature
Identification of verified dosimetric parameters associated with swallowing and nutritional outcomes posttreatment was conducted through a systematic review of the literature. Electronic publications in English between January 1990 and May 2011 were searched for by the first author (B.C.). CINAHL, Pre-CINAHL, EMBASE, Medline, and PubMed databases were searched using keywords, subject heading words, titles, and abstracts. The following medical subject headings (MeSH) search terms were used: deglutition, deglutition disorders, intensity modulated radiotherapy, radiotherapy, and head and neck neoplasms. Additional search terms included swallowing, dysphagia, aspiration, videofluoroscopy, dosimetry, dose-volume constraints, dose-volume histogram, and head and neck cancer. Studies were included if: (1) participants were diagnosed with head and neck cancer; (2) specific swallowing-related structures were outlined; (3) total, mean, median, maximum, or partial doses of radiotherapy to specific swallowing-related structures were reported; (4) ''dysphagia outcomes'' were reported at 1 or more time points posttreatment and included at least 1 of the following: dysphagia toxicity, aspiration, physiologic swallowing impairment, stricture, patient-reported swallowing function, diet tolerance, swallowing-related or general quality of life, and/or dependence on alternative feeding. Studies were excluded if: (1) participants were diagnosed with cancer other than that defined to the head and neck area; (2) anatomic structures outlined related specifically to outcomes other than swallowing (ie, saliva, skin, voice, edema, anatomic change); (3) dysphagia outcome was not reported; (4) radiotherapy dose to swallowing-related structures was not reported; or (5) the relationship between the dysphagia outcome and radiotherapy dose was not reported.
Following this search strategy, the reference lists of identified articles were manually searched for additional relevant publications. All relevant publications were reviewed by 2 researchers (B.C. and R.N.) and rated for methodologic quality based on the Transparent Reporting of Evaluations with Nonrandomized Designs (TREND) checklist, developed to be consistent with the Consolidated Standards or Reporting Trials (CONSORT) statement for randomized controlled trials. 26 The 22 criteria specified by TREND were given a rating of 1 (satisfies the criteria) or 0 (does not satisfy the criteria), yielding a possible total quality rating of 22.
A total of 18 studies met the criteria to be included in this review, of which 1 was a systematic review and another of these papers was a review of results reported by 2 other studies, and was therefore excluded. 15 The remaining 16 were a variety of nonrandomized designs, and were evaluated in detail and given a quality rating using the 22-item TREND checklist. 26 The 2 researchers (B.C. and R.N.) subsequently met to compare their ratings and an agreed consensus was reached. Analysis revealed that the average score for quality of methodology was 14.6 (range, 11-17), with higher scores representative of an article meeting a greater number of methodologic criteria (Table 1) . Dosimetric data were collated from the articles regarding specific swallowing structures. These included the base of tongue (BOT), pharyngeal constrictors (PCs, as a single structure), as well as superior (SPC), middle (MPC), and inferior (IPC) pharyngeal constrictors, glottic/supraglottic larynx (GSL), upper esophageal sphincter (UES), and esophagus (ES). From this, only the most conservative evidence-based dose constraints for these swallowing structures were collated from the literature reviewed (see Figure 2 ). For example, if dose constraints of V 50 < 50 Gy, V 50 < 55 Gy or V 60 < 50 Gy to the BOT were reported in separate studies, then V 50 < 50 Gy was included in the summary as the most conservative dose reported.
Application of known dosimetric parameters
The second component of the current study aimed to determine whether those dose constraints identified in the literature as associated with swallowing outcomes posttreatment were accurate at identifying swallowing, nutrition, and patient-rated functional impairment. As such, the dosimetric details of a homogeneous cohort of patients who received 3D conformal AFRT-CB for T1-T3 oropharyngeal squamous cell carcinoma (SCC) were generated and applied to their swallowing, nutrition, and patient-rated outcomes.
Participants
The cohort included 12 participants taken from a group of 14 participants described previously in a prospective study examining functional outcomes. 27 Demographic details are reported in Table 2 , and maximum, mean, and V 40 , V 50 , and V 60 partial doses received by this cohort are reported in Table 3 . Two participants from the original cohort were excluded because 1 participant's radiotherapy planning data were unable to be restored (AF05), and for another the imaging was of insufficient quality to accurately delineate the target structures (AF04). Data analysis was, therefore, completed on the 12 participants who completed treatment and follow-up at 6 months posttreatment, and for whom accurate dose-volume histograms could be generated. No patient received chemotherapy or targeted therapies. All patients received their treatment at the Metro South Radiation Oncology Service in Brisbane, Australia. Ethics approval was obtained from the Princess Alexandra Hospital and The University of Queensland Human Research and Ethics Committees, and all participants provided written consent prior to their involvement.
Planned treatment and dose-volume histogram contouring
Participants were treated with AFRT-CB of 66 Gy in 35 fractions over 5 weeks using 3D conformal planning FIGURE 2. Dose parameters recorded for swallowing structures reported in the literature (study identified with alphabetical identifier as in Table  1 ) as relevant for swallowing outcomes. BOT, base of tongue; PC, pharyngeal constrictor; GSL, glottic/supraglottic larynx; UES, upper esophageal sphincter; ES, esophagus; IPC, inferior pharyngeal constrictor; MPC, middle pharyngeal constrictor; SPC, superior pharyngeal constrictor.
techniques in accord with our institutional head and neck cancer treatment protocol. In the final 2 weeks of treatment, participants were given a second daily dose of 1.6 Gy with at least 6-hour interfraction interval. Planning target volumes (PTVs) were as follows: PTV1 to cover the primary and involved nodal regions and potential areas of local extension or lymphatic spread (gross target volume [GTV] þ 1.5 cm plus potential areas of spread to nodes), and PTV2 to primary and involved node regions (GTV þ 1.0 cm). Contralateral nodes were included in the treatment field in patients with supraglottic and base of tongue disease or where there were pathologic nodes in the ipsilateral neck. 28 Unilateral treatment was given in patients with oropharyngeal disease where the ipsilateral neck was N0. 28 On completion of treatment, dose-volume histograms were generated for each participant to capture 8 structures critical for swallowing in each participant. Two specialist radiation oncologists (S.P. and M.P.) supervised 2 junior medical staff (C.B. and R.M.R.) in the accurate delineation of the target structures using CT imaging. From this information, dose-volume histograms of the base of tongue, pharyngeal constrictor, superior pharyngeal constrictor, middle pharyngeal constrictor, inferior pharyngeal constrictor, glottic/supraglottic larynx, upper esophageal sphincter, and esophagus were generated using the Eclipse Treatment Planning System version 8.6 (Varian Medical Systems, Palo Alto, CA). The procedure for dose-volume histogram generation was that described by the Trans-Tasman Radiation Oncology Group (TROG) in the 07.04 protocol (TROG registered number: A0031029V), and abided by anatomic boundaries described previously. 4, 12, 13, 16 Copies of the pictorial dose-volume histograms, as well as descriptive data regarding mean and maximum doses to each structure were provided to the principal investigator for analysis. Dose-volume histograms were analyzed for the following endpoints to determine: the percentage volume to the base of tongue, pharyngeal constrictor, superior pharyngeal constrictor, middle pharyngeal constrictor, inferior pharyngeal constrictor, glottic/supraglottic larynx, upper esophageal sphincter, and esophagus receiving partial doses of 40 Gy (V 40 ), 50 Gy (V 50 ), 60 Gy (V 60 ), the mean dose (M D ), and the maximum dose (Max D ). The dosimetric data of each individual were then compared with the parameters in Figure 2 and coded as either 0 (structure received mean dose of less than that verified by the literature) or 1 (structure received mean dose of greater than that verified by the literature) for all 8 swallowing structures. This identified which patients received doses to specific structures that met or exceeded suggested dose constraints to each swallowing structure.
Outcome measures
The coded dose constraints (did or did not meet the criteria outlined in Figure 2 ) were then analyzed against 11 endpoints measured at 6 months posttreatment in the AFRT-CB cohort to explain whether adherence to specific dosimetric parameters accurately identified who would be impaired/unimpaired posttreatment. These 12 endpoints included: (1) xerostomia and dysphagia toxicity grades 0-4 in accord with the Common Toxicity Criteria for Adverse Events version 3.0 (CTCAE v.3.0 29 ); (2) full diet versus modified diet following following clinical swallow evaluation (CSE); (3) functional swallowing status using the Royal Brisbane Hospital Outcome Measure for Swallowing (RBHOMS) score (scores of 1-7 ¼ impaired vs scores 8-10 ¼ not impaired) 30 following CSE; (4) physiologic swallowing impairment in pharyngeal contraction/bolus propulsion, laryngeal excursion, and clearance of pyriform sinus residue (0 ¼ not impaired; 1 ¼ impaired) using Subscale One of the New Zealand Index for Multidisciplinary Evaluation of Swallowing (NZIMES), 31 following videofluoroscopy [VFS]); (5) the presence of penetration or aspiration using the validated Penetration-Aspiration Scale (PAS), 32 using VFS; (6) general patient-rated function using the Functional Assessment of Cancer Therapy Additional Concerns for Head and Neck version 4 (FACT-H&N), 33 Head and Neck Specific score (score < 36 ¼ impaired); (7) response FACT-H&N to question 7: ''I can swallow naturally and easily'' (scores 3-4 ¼ not impaired; scores 0-2 ¼ impaired); (8) patient-rated swallowing function using the MD Anderson Dysphagia Inventory (MDADI) 34 global score (score <100 ¼ impaired); (9) response to MDADI physical question 6: ''swallowing takes me great effort'' (scores 3-5 ¼ not impaired; scores 1, 2 ¼ impaired); (10) global nutrition using the Patient-Generated Subjective Global Assessment (PG-SGA), 35 global score of A (not impaired) vs B or C (impaired); (11) loss of weight (LOW) of >10% between pretreatment and 6 months posttreatment; and (12) requirement of alternative feeding at any time during or posttreatment.
Statistical analysis
Receiver operating characteristic (ROC) analysis was used to determine which dose constraints accurately identified impairment in toxicity, dysphagia, patient-rated functional impact, or nutrition endpoints at 6 months posttreatment in the AFRT-CB cohort. The data meeting the following 2 criteria were considered clinically important if: (1) the area under the curve (AUC) was >0.75, and (2) the ROC curve assessed >75% of the participants correctly (ie, met dose constraints and not impaired, plus exceeded dose constraints and impaired).
RESULTS
Thirty-eight radiation dosimetric parameters were identified in the literature, and 25 of those (66%) accurately identified the presence/absence of impairment in the AFRT-CB cohort at 6 months posttreatment. Tables 4  and 5 report the ROC analyses meeting both clinically important criteria outlined above for toxicity/swallowing, and patient-rated functional impact/nutritional endpoints, respectively.
Analysis revealed specific partial doses to the base of tongue, superior pharyngeal constrictor, and glottic/supraglottic larynx correctly identified ongoing salivary or dysphagia toxicity at 6 months posttreatment. Additionally, a mean dose of >51 Gy to the superior pharyngeal constrictor also identified ongoing salivary toxicity posttreatment. There were 13 dose constraints verified in the literature that correctly identified penetration and aspiration events (for fluids) in the current cohort (Table 4) . Partial doses to the pharyngeal constrictor (V 65 ), middle pharyngeal constrictor (V 65 ), inferior pharyngeal constrictor (V 45 -V 60 ), glottic/supraglottic larynx (V 65 ), upper esophageal sphincter (V 60 , V 65 ), and esophagus (V 40 ) all correctly identified penetration and aspiration of fluids at 6 months posttreatment. Mean dose to the glottic/supraglottic larynx of >48 Gy, maximum dose to the upper esophageal sphincter of >60 Gy, and mean dose to the esophagus of >17 Gy also correctly identified penetration and aspiration of fluids at 6 months. Other measures of physiologic swallowing impairment (laryngeal excursion or clearance of pharyngeal residue) were correctly identified by partial doses to the base of tongue, pharyngeal constrictor, superior pharyngeal constrictor, and inferior pharyngeal constrictor (Table 4) . Additionally, partial doses to the base of tongue, superior pharyngeal constrictor, and glottic/supraglottic larynx correctly identified impairment in functional swallowing (with respect to Royal Brisbane Hospital Outcome Measure for Swallowing) or the need for a modified diet at 6 months posttreatment (Table 4) . A number of verified dose constraints also correctly identified some patient-rated functional impact and nutrition outcomes at 6 months posttreatment (Table 5) . Only the mean (>51 Gy) and V 40 partial (<95%) doses to the superior pharyngeal constrictor correctly identified patient-rated functional impact for head and neck-specific concerns on the FACT-H&N, and responses to the statement ''I can swallow naturally and easily.'' All other dose constraints did not correctly identify any other patient-rated functional impact outcomes. Mean doses to the inferior pharyngeal constrictor (<32 Gy) and upper esophageal sphincter (<23 Gy), as well as partial doses to the pharyngeal constrictor (V 50 ), inferior pharyngeal constrictor (V 40 ), and glottic/supraglottic larynx (V 35 , V 70 ) correctly identified the presence or absence of global nutritional impairment at 6 months posttreatment. A 10% loss of weight was correctly identified by partial doses to the base of tongue (V 50 ) and superior pharyngeal constrictor (V 50 ) ( Table 5 ).
DISCUSSION
The emerging evidence identifying radiation dosimetric factors that have an impact on swallowing and nutritional outcomes posttreatment is novel and innovative. The purpose of the current study was to highlight the accuracy of previously reported dose constraints in detailing a range of swallowing and nutritional outcomes at 6 months posttreatment, and has added to the emerging evidence in this area in two ways. First, this study provides evidence that 66% of radiation dosimetric parameters verified by the literature accurately identify swallowing and nutritional outcomes at 6 months posttreatment in a cohort of patients with oropharyngeal SCC treated with AFRT-CB, despite the methodologic limitations of previous research. Second, this study presents seminal evidence for the impact of radiation dosimetric parameters on global nutritional status and percentage weight loss at 6 months posttreatment.
Current evidence for dosimetric constraints and swallowing outcomes
The current evidence base is small, generally retrospective in design, and has commonly used heterogeneous head and neck cohorts, thus limiting the generalizability of dose constraint recommendations into clinical populations with head and neck cancer. Furthermore, there is a very high degree of methodologic variability between the tools used to determine the presence of dysphagia with assessment procedures varying from crude rating scales performed by medical staff 11, 13, 16, 17, 36 to detailed VFS assessments performed by speech pathologists. 12, 22, 37 Similarly the variability between the outcome time points scored also varies dramatically. The majority of papers have compared the dosimetric parameters to swallowing outcomes at only 1 time point posttreatment, and this ranges from 4 to 8 weeks 11 to more than 7 years posttreatment. 18 Some of the relationships have been established on outcomes seen as early as 3 months posttreatment, 16, 20, 21 whereas most of the work has explored relationships to long-term outcomes at either 6 months 20, 22, 36 or beyond. 10, [12] [13] [14] [18] [19] [20] [21] [22] [23] 25 Very few papers routinely scored outcomes at multiple time points posttreatment. [20] [21] [22] 36 Furthermore, the specific types of outcomes vary between studies, with authors commenting on dose constraints to reduce dysphagia toxicity, aspiration, physiologic impairment, stricture formation, patientreported dysphagia, quality of life, and the need for alternative feeding. Thus, it becomes obvious by examining this variability in methodology between studies that consistency in the recording and reporting of a core set of specific dysphagia and nutritional outcomes needs to be established.
Application of verified dosimetric parameters to an AFRT-CB cohort
The current study has found two thirds of published dose constraints accurately identified toxicity, swallowing, nutrition, and patient-rated function impairment at 6 months posttreatment in the current AFRT-CB cohort. Those dose constraints included partial doses to the base of tongue, pharyngeal constrictor, superior pharyngeal constrictor, middle pharyngeal constrictor, inferior pharyngeal constrictor, glottic/supraglottic larynx, upper esophageal sphincter, and esophagus, as well as mean doses to the superior pharyngeal constrictor, inferior pharyngeal constrictor, glottic/supraglottic larynx, upper esophageal sphincter, and esophagus, and maximum dose to the upper esophageal sphincter. Conversely, several of the dose constraints previously reported did not accurately identify impairment in the AFRT-CB cohort at 6 months posttreatment, indicating further detailed and systematic study is required.
Previously, a partial dose to the base of tongue of 50% receiving >50 Gy had been associated with aspiration 18 ; however, the current study revealed this dose constraint also accurately identified impairment in salivary toxicity, laryngeal excursion, the need for a modified diet, and weight loss at 6 months posttreatment. It is not an unexpected result that the dose to the base of tongue, closely aligned with the parotid glands, is associated with longterm xerostomia. The impact of xerostomia on dietary modifications and subsequent weight loss has also been reported previously, 38, 39 and it is not unanticipated that these impairments have co-occurred in the current cohort. The finding of impaired laryngeal excursion associated with base of tongue partial dose may reflect airway protection impairment. Adequate laryngeal excursion is necessary for epiglottic deflection and airway protection, and if impaired may result in penetration and aspiration as found by Jensen et al. 18 Similarly, the co-occurrence of the need for a modified diet and weight loss both identified with a partial dose to the superior pharyngeal constrictor of 90% receiving 50 Gy. Feng and colleagues 16 suggested partial V 50 dose to the superior pharyngeal constrictor be reduced to 90% to avoid aspiration, although in the current cohort neither aspiration nor penetration of fluids or solids was correctly identified with this dose constraint.
Mean, maximum, and partial doses to the middle pharyngeal constrictor, inferior pharyngeal constrictor, glottic/supraglottic larynx, upper esophageal sphincter, and esophagus verified by the literature showed strong identification of penetration and aspiration events in the current cohort. It appears that larger doses to these structures are a potential contributing factor to aspiration risk at 6 months posttreatment. With significant aspiration, often alternative feeding is recommended. Very few of the current cohort required short-term nasogastric tube feeding, although Caudell et al 12 found conservative partial doses to the inferior pharyngeal constrictor from V 45 to V 60 were not associated with the need for alternative feeding. Thus, our results may confirm that the partial doses suggested by Caudell et al 12 do accurately identify those at risk for alternative feeding as a result of penetration or aspiration. Only 3 of the suggested dose constraints to the glottic/supraglottic larynx to reduce aspiration (mean dose < 48 Gy) 11 and alternative feeding (V 65 < 23% and V 70 < 4%) 12 correctly identified those who penetrated/aspirated at 6 months posttreatment in the current cohort. Upper esophageal sphincter partial doses receiving 60 and 65 Gy, however, accurately identified penetration and aspiration, whereas the literature has previously reported an association with stricture formation and patientreported dysphagia not found in this study. 20 The upper esophageal sphincter dose parameter previously associated with aspiration (V 40 < 50%), 18 did not correctly identify it in the current cohort. Both esophageal doses previously associated with aspiration correctly identified penetration and aspiration in the current cohort (mean dose, <17 Gy 23 ; V 40 < 88% 16 ). Global nutritional outcome was correctly identified by mean and partial doses to the inferior pharyngeal constrictor, glottic/supraglottic larynx, and upper esophageal sphincter. Global nutritional outcome has not previously been assessed in relation to dosimetric parameters, so this study provides the first evidence that parameters that have previously been associated with dysphagia toxicity (inferior pharyngeal constrictor mean dose, <32 Gy), 19 alternative feeding (inferior pharyngeal constrictor V 40 < 65% and glottic/supraglottic larynx V35 < 79%), 12 and aspiration (upper esophageal sphincter mean dose, <23 Gy) 23 also correctly identify those patients who will be at risk of malnutrition at 6 months posttreatment. In the general head and neck cancer population, it could be hypothesized that dysphagia toxicity (grade 4 toxicity requiring alternative feeding), the need for alternative feeding, and aspiration would result in poor global nutritional status, so this finding confirms the clinical relevance of these dosimetric parameters.
Although the evidence base is as yet small, current research has proposed a number of dosimetric constraints to key swallowing structures that may be influential in minimizing the negative impact on swallowing, and potentially nutritional outcomes, following radiotherapy. Unfortunately, the number of significant methodologic weaknesses in the current available literature must be acknowledged when interpreting the data at this time. Despite this, the application of the existing dosimetric parameters identified in the literature to our current cohort revealed that over two thirds were consistent with the patient outcomes achieved. Future studies examining the predictive power of dosimetric factors need to include pretreatment data, agreement on which swallowing organs at risk are contoured and how, and include outcome measure assessment that addresses the multifactorial nature of dysphagia and nutritional impairment, and uses validated measures. It is the hope that future rigorous, multidisciplinary studies will guide radiation oncologists and radiation therapists to optimize treatment plans and dose gradients to structures identified as associated with poor functional outcomes, allowing speech pathologists, dietitians, and nurses involved in the rehabilitation of this population to better identify those patients at risk of developing dysphagia and/or nutritional compromise at 6 months posttreatment. Accordingly, this knowledge may guide alternative service delivery in the posttreatment phase to prevent functional impairment for those at risk.
